# Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for The

Source: https://onco.cc/trials/nct05927142/  
OnCo record `nct05927142` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of durvalumab in pancreatic cancer, run by Joachim Aerts, MD PhD, now recruiting.

## Summary

Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy is a phase 1/2, interventional study registered as NCT05927142 by Joachim Aerts, MD PhD, with a registry enrolment figure of 43 participants, started 2024-01-09 and due to reach its primary completion in 2026-04. Interventions recorded: Durvalumab; Rintatolimod. Conditions listed: Metastatic Pancreatic Cancer. Primary outcome: Phase Ib: Determine safety of combination therapy with durvalumab and rintatolimod; Phase II: Determine the clinical benefit rate of combination therapy with durvalumab and rintatolimod.. Pancreatic eligibility wording from the registry: "* Histologically or cytologically (Bethesda 5 or 6) confirmed metastatic pancreatic cancer, as indicated by a definite cytology/histology report". Sites: Netherlands. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: DURIPANC
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT05927142
- Phase: 1/2
- Setting: Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy
- Sponsor: Joachim Aerts, MD PhD
- Enrolled: 43

## Sources

- ClinicalTrials.gov NCT05927142: https://clinicaltrials.gov/study/NCT05927142

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05927142.json